An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV

Hailong Guo(IGM Biosciences (United States)), Tong‐Ming Fu(Doylestown Hospital), Paul R. Hinton(IGM Biosciences (United States)), Christopher Mensch(IGM Biosciences (United States)), Sameer Sachdeva(University of the Pacific), Bomsoo Cho(IGM Biosciences (United States)), Zhiqiang An(Xiamen University), Ashwin Ramesh(Brown Foundation), Jason Botten(University of Vermont), Zhiqiang Ku(Brown Foundation), Philip Eisenhauer(University of Vermont), Stephen F. Carroll(IGM Biosciences (United States)), Rebekah Honce(University of Vermont), Yongjun Yu(IGM Biosciences (United States)), Annalis Whitaker(University of Vermont), Kai Xu(Memorial Sloan Kettering Cancer Center), Mohamed Dawod(IGM Biosciences (United States)), William R. Strohl(Bridgewater State University), Sha Ha(IGM Biosciences (United States)), Bruce A. Keyt, Sijia He(IGM Biosciences (United States)), Sarah Holland(IGM Biosciences (United States)), Ningyan Zhang(Brown Foundation), Allison Falcone(University of Vermont), Andrew W. Womack(IGM Biosciences (United States)), Jwala Priyadarsini Sivaccumar(Brown Foundation), Kristen Campo(IGM Biosciences (United States)), John W. Shiver(IGM Biosciences (United States))
Emerging Microbes & Infections
December 8, 2023
Cited by 5


Related Papers